Letters sent to healthcare professionals in June 2018

Letters were sent about Cetrotide (cetrorelix acetate), Eperzan鈻�(albiglutide), darunavir/cobicistat, Keytruda鈻� (pembrolizumab), Denzapine (clozapine) 50 mg/mL oral suspension, and Bleo-Kyowa (bleomycin sulphate).

From:
Medicines and Healthcare products Regulatory Agency
Published
17 July 2018
Therapeutic area:
Anaesthesia and intensive care, Cancer, Cardiovascular disease and lipidology, Haematology and oncology and Immunosuppression and transplantation
Show 5 more
Infectious disease, Obstetrics, gynaecology and fertility, Paediatrics and neonatology, Psychiatry, and Urology and nephrology

  • Cetrotide (cetrorelix acetate):

  • 贰辫别谤锄补苍鈻�(补濒产颈驳濒耻迟颈诲别):

  • Darunavir/cobicistat:

  • Keytruda鈻� (pembrolizumab):

  • Denzapine 50 mg/mL Oral Suspension (clozapine): , see company-led recall

  • Bleo-Kyowa (bleomycin sulphate), powder for solution for injection: , see class 4 medicines defect information

Please continue to submit your thoughts on how we can improve the communication of medicines safety issues to support safe and effective use. Complete this today.

Article citation: Drug Safety Update volume 11, issue 12; July 2018: 6.

Updates to this page

Published 17 July 2018

Related content